EMA Authorised: Spectrila (asparaginase) — Medac Gesellschaft fuer klinische Spezialpraeparate mbH

View source ↗

Summary

The EMA authorised Spectrila (asparaginase) for precursor cell lymphoblastic leukemia-lymphoma (ALL/LBL) in collaboration with Medac as the marketing authorizat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Precursor Cell Lymphoblastic Leukemia-lymphoma

Drugs mentioned

• Spectrila (pegaspargase)

Snippet

Status: Authorised. Therapeutic area: Precursor Cell Lymphoblastic Leukemia-Lymphoma. MAH: Medac Gesellschaft fuer klinische Spezialpraeparate mbH. Decision date: 09/03/2023